Pooled Sample Testing for SARS-CoV-2
Hyde, B. L.; Berke, E.; Verma, P.
Show abstract
We tested an operationally efficient way to pool samples on a rapid, point-of-care PCR device and examined the limit of detection of SARS-CoV-2 for various pool sizes. Pooled testing maintained testing performance similar to individual sample PCR testing, offering the potential for scalable rapid testing at lower cost with less supplies.
Matching journals
The top 7 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Recommendations for sample pooling on the Cepheid GeneXpert(R) system using the Cepheid Xpert(R) Xpress SARS-CoV-2 assay 95%
- Clinical evaluation of the Diagnostic Analyzer for Selective Hybridization (DASH): a point-of-care PCR test for rapid detection of SARS-CoV-2 infection 95%
- Performance of the TaqMan™ COVID-19 Pooling Kit for detection of SARS-CoV-2 in Asymptomatic and Symptomatic populations at an Institution of Higher Education 94%
Similar papers in this journal
- Performance of the Cue COVID-19 Molecular Test for Point of Care: Insights from a multi-site clinic service model 96%
- Evaluation of the INDICAID™ COVID-19 Rapid Antigen Test in symptomatic populations and asymptomatic community testing 94%
- Analytical comparison of over-the-counter multiplex tests for influenza A, influenza B and SARS-CoV-2 94%
Similar papers in this journal
- Estimating the false positive rate of highly automated SARS-CoV-2 nucleic acid amplification testing 95%
- Assessment of sample pooling for clinical SARS-CoV-2 testing 94%
- A multicenter study to assess the performance of the point-of-care RT-PCR Cobas SARS-CoV-2 & Influenza A/B nucleic acid test for use on the Cobas Liat system in comparison with centralized assays across healthcare facilities in the United States 94%
Similar papers in this journal
- Analytical Performance of the AMDI Fast PCR Mini Respiratory Panel 94%
- Practical strategies for SARS-CoV-2 RT-PCR testing in resource-constrained settings 94%
- Comparative study of four SARS-CoV-2 Nucleic Acid Amplification Test (NAAT) platforms demonstrates that ID NOW performance is impaired substantially by patient and specimen type. 93%
Similar papers in this journal
- Evaluation of the Access Bio CareStart™ rapid SARS-CoV-2 antigen test in asymptomatic individuals tested at a community mass-testing program in Western Massachusetts 93%
- Validation of a rapid, saliva-based, and ultra-sensitive SARS-CoV-2 screening system for a pandemic-scale infection surveillance 93%
- Performance evaluation of a non-invasive one-step multiplex RT-qPCR assay for detection of SARS-CoV-2 direct from human saliva 92%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.